We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+1.66%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.45B
AUM Growth
+$98.6M
Cap. Flow
+$39.6M
Cap. Flow %
1.62%
Top 10 Hldgs %
39.51%
Holding
166
New
25
Increased
26
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$38M
2
COR icon
Cencora
COR
+$30.2M
3
CVS icon
CVS Health
CVS
+$22.3M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$21M
5
GILD icon
Gilead Sciences
GILD
+$16M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$36M
2
MDVN
MEDIVATION, INC.
MDVN
+$23.3M
3
NVO
Novo Nordisk
NVO
+$16M
4
VTR icon
Ventas
VTR
+$14.3M
5
DOC
PHYSICIANS REALTY TRUST
DOC
+$13.4M

Sector Composition

Rank Sector Weight
1 Healthcare 86.46%
2 Real Estate 2.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IPXL
101
DELISTED
Impax Laboratories, Inc.
IPXL
$3.58M 0.15%
124,335
– –
CYTO
102
DELISTED
Altamira Therapeutics Ltd
CYTO
$3.5M 0.14%
10
– –
ONC
103
BeOne Medicines Ltd
ONC
$33.4B
$3.48M 0.14%
116,707
– –
PRGO icon
104
Perrigo
PRGO
$1.43B
$3.38M 0.14%
37,300
– –
KPTI icon
105
Karyopharm Therapeutics
KPTI
$159M
$3.36M 0.14%
33,355
– –
AZN icon
106
CALL
AstraZeneca
AZN
$266B
$3.33M 0.14%
+55,100
New +$3.2M
COR icon
107
CALL
Cencora
COR
$60.7B
$3.29M 0.13%
+41,500
New +$3.33M
GSK icon
108
CALL
GSK
GSK
$104B
$3.26M 0.13%
+60,160
New +$3.17M
CELG
109
CALL
DELISTED
Celgene Corp
CELG
$3.08M 0.13%
+31,200
New +$3.23M
WMGI
110
CALL
DELISTED
Wright Medical Group Inc
WMGI
$2.94M 0.12%
+169,000
New +$3.1M
MCK icon
111
McKesson
MCK
$101B
$2.8M 0.11%
15,000
-67,862
-82% -$11.9M
GRFS
112
Grifois
GRFS
$5.58B
$2.77M 0.11%
166,000
– –
NVAX icon
113
Novavax
NVAX
$1.22B
$2.6M 0.11%
17,900
– –
FWP
114
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$2.48M 0.1%
19,507
– –
ADAP
115
DELISTED
Adaptimmune Therapeutics
ADAP
$2.42M 0.1%
296,934
– –
ORKA
116
Oruka Therapeutics
ORKA
$5.9B
$2.35M 0.1%
3,756
– –
CCP
117
DELISTED
Care Capital Properties, Inc.
CCP
$2.21M 0.09%
84,316
– –
MDRX
118
DELISTED
Veradigm Inc. Common Stock
MDRX
$2.21M 0.09%
173,600
– –
DBVT
119
DBV Technologies
DBVT
$817M
$2.14M 0.09%
6,560
– –
BLUE
120
DELISTED
bluebird bio
BLUE
$2.14M 0.09%
3,809
– –
MRUS
121
DELISTED
Merus
MRUS
$2.11M 0.09%
+260,000
New +$2.27M
GBT
122
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.07M 0.08%
+125,000
New +$2.52M
KITE
123
DELISTED
Kite Pharma, Inc.
KITE
$2.05M 0.08%
41,000
– –
NTLA icon
124
Intellia Therapeutics
NTLA
$1.55B
$1.85M 0.08%
+86,842
New +$2.31M
ADYX
125
DELISTED
Adynxx Inc
ADYX
$1.85M 0.08%
27,500
– –
3 4
5
6 7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, Tekla Capital Management held 166 positions worth $2.45B, up 4.2% from $2.35B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q2 2016 filing shows 25 new, 26 increased, 19 reduced and 10 closed positions. Its largest new stake was Abbott: 953,500 shares worth $37.5M. The largest sale was Celgene Corp, an estimated $36M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 87% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2016 buy was Abbott: 953,500 shares worth $37.5M.
  • Tekla Capital Management added most to Neurocrine Biosciences in Q2 2016, an estimated $21M increase.
  • Tekla Capital Management's biggest Q2 2016 reduction was Celgene Corp, cutting an estimated $36M.
  • Tekla Capital Management fully exited Novo Nordisk in Q2 2016, selling an estimated $16M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.45B portfolio in Q2 2016.
  • Tekla Capital Management opened 25 new positions and closed 10 in Q2 2016.
  • Tekla Capital Management's portfolio value rose 4.2% quarter-over-quarter to $2.45B.

Based on Tekla Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.